Ibandronic acid
Ibandronic Acid Viatris belongs to a group of medicines called bisphosphonates. It contains the active substance ibandronic acid.
Ibandronic Acid Viatris can reverse bone loss by inhibiting bone loss and increasing bone mass in most women taking this medicine, even if they do not notice or feel the difference. Ibandronic Acid Viatris may help reduce the risk of fractures (breaks) in bones. A reduction in the number of fractures has been shown in the case of vertebral fractures, but not in the case of hip fractures.
Osteoporosis is a disease characterized by a decrease in bone density and weakening of bones, which often occurs in women after menopause. During menopause, the female ovaries stop producing the female hormone - estrogen, which helps maintain normal bone structure.
The earlier menopause occurs in a woman, the higher her risk of fractures related to osteoporosis.
Other factors that may increase the risk of fractures include:
A healthy lifestylewill also help achieve the greatest benefits from treatment. This means:
After the marketing of ibandronic acid, a rare side effect called necrosis of the jawbone and (or) jaw (damage to the jawbone and (or) jaw) has been reported in patients treated with ibandronic acid for osteoporosis. Necrosis of the jawbone and (or) jaw may also occur after treatment has stopped.
It is essential to take preventive measures to avoid the development of necrosis of the jawbone and (or) jaw, as it can be a painful and difficult condition to treat. To reduce the risk of necrosis of the jawbone and (or) jaw, appropriate precautions should be taken.
In patients receiving long-term ibandronic acid treatment, atypical fractures of long bones, such as the forearm (ulna) and shinbone, have also been reported. These fractures occur with minimal trauma or without trauma, and some patients experience pain at the fracture site before the fracture occurs.
Before starting treatment, you should tell your doctor or nurse (healthcare professional):
Your doctor may recommend that you have a dental check-up before starting treatment with Ibandronic Acid Viatris.
During treatment, you should maintain good oral hygiene (including regular tooth brushing) and have regular dental check-ups. If you wear dentures, you should ensure they fit properly. If you are undergoing dental treatment or dental procedures (e.g., tooth extraction), you should inform your doctor and dentist that you are taking ibandronic acid.
If you experience any oral or dental problems, such as loose teeth, pain, or swelling, non-healing ulcers, or discharge, you should contact your doctor and dentist immediately, as these may be symptoms of necrosis of the jawbone and (or) jaw.
Some people need to be more careful when taking ibandronic acid. Before starting treatment with Ibandronic Acid Viatris, you should discuss this with your doctor or pharmacist:
There may be irritation, inflammation, or ulcers of the esophagus, often with symptoms of severe chest pain, severe pain after swallowing food or drink, severe nausea, or vomiting, especially if you do not drink a full glass of plain water or lie down within an hour of taking ibandronic acid. If such symptoms occur, you should stop taking Ibandronic Acid Viatris and consult your doctor immediately (see section 3).
Do not give Ibandronic Acid Viatris to children and adolescents under 18 years of age.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, especially:
After taking the monthly tablet of Ibandronic Acid Viatris, wait for 1 hour
before taking any other medicines, including antacids or calcium and vitamin supplements.
Do not take Ibandronic Acid Viatris with food. Ibandronic Acid Viatris taken with food is less effective.
After taking Ibandronic Acid Viatris, wait for 1 hour before eating or drinking anything else (see section 3 "How to take Ibandronic Acid Viatris").
Ibandronic Acid Viatris is used only in postmenopausal women and should not be used by women who may become pregnant.
Do nottake Ibandronic Acid Viatris during pregnancy or breastfeeding.
Consult your doctor or pharmacist before taking this medicine.
You can drive and use machines, as Ibandronic Acid Viatris has no or negligible influence on the ability to drive and use machines.
This medicine contains lactose monohydrate. If you have been diagnosed with intolerance to some sugars, you should consult your doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which is essentially "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
It is essential to follow these instructions carefully. These instructions have been designed to help the tablet reach the stomach quickly, reducing the risk of irritation.
Do notdrink water with high calcium content, fruit juice, or any other beverage. If you are concerned about potentially high calcium levels in tap water (hard water), it is recommended to use bottled water with low mineral content.
Do nottake Ibandronic Acid Viatris before going to bed or before getting up in the morning.
It is essential to take Ibandronic Acid Viatris every month, as long as your doctor recommends. After 3-5 years of taking Ibandronic Acid Viatris, you should consult your doctor to determine if you should continue taking Ibandronic Acid Viatris.
If you accidentally take more than one tablet, drink a full glass of milk
and contact your doctor immediately.
Do notinduce vomiting and do not lie down- this may cause irritation of the esophagus by Ibandronic Acid Viatris.
same week.Wait until your next scheduled dose and take one tablet according to your original schedule.
Take one tablet the next morning after the day you remembered you missed a dose, and then continue taking one tablet per month on the scheduled days marked on your calendar.
Like all medicines, Ibandronic Acid Viatris can cause side effects, although not everybody gets them.
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
If you experience any side effects, including those not listed in this leaflet, please inform your doctor, pharmacist, or nurse. You can also report side effects directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309, website: https://smz.ezdrowie.gov.pl
You can also report side effects to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
There are no special storage precautions.
Do not use this medicine after the expiry date stated on the carton and blister after "EXP". The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance is ibandronic acid in a dose of 150 mg (as sodium ibandronate monohydrate).
The other ingredients are:
The medicine is a white, coated tablet, capsule-shaped, biconvex, with "G" over "I-150" printed in black ink on one side and a smooth surface on the other.
Ibandronic Acid Viatris is available in blisters of 1 and 3 tablets, in a cardboard box.
Not all pack sizes may be marketed.
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
DUBLIN
Ireland
Manufacturer/Importer:
McDermott Laboratories Limited (t/a Gerard Laboratories)
35/36 Baldoyle Industrial Estate
Grange Road, Dublin 13
Ireland
Pharma Pack Kft
2040 Budaörs
Vasút u. 13
Hungary
Mylan Hungary Kft.
H-2900 Komárom
Mylan utca 1.
Hungary
To obtain more detailed information on this medicine and its authorized names in the Member States of the European Economic Area, please contact the local representative of the marketing authorization holder:
Tel: +48 22 546 64 00
Date of last revision of the leaflet:May 2025
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.